CII
IPXL

CR Intrinsic Investors’s Impax Laboratories, Inc. IPXL Stock Holding History

CR Intrinsic Investors’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-289,815
Closed -$5.94M – 411
2013
Q3 		$5.94M Buy
289,815
+31,815
+12% +$657K 0.18% 171
2013
Q2 		$5.15M Buy
+258,000
New +$4.58M 0.18% 174

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CR Intrinsic Investors's IPXL Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Impax Laboratories, Inc. (IPXL) in Q4 2013, closing a stake of 289,815 shares — an estimated $5.94M sold.

CR Intrinsic Investors first reported a position in IPXL in Q2 2013 and held it in 2 quarters. The position peaked at $5.94M in Q3 2013. 166 funds tracked by Wall St. Rank hold IPXL as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Impax Laboratories, Inc. position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 289,815 Impax Laboratories, Inc. shares in Q4 2013, an estimated $5.94M.
  • CR Intrinsic Investors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 2 quarters.
  • CR Intrinsic Investors's Impax Laboratories, Inc. position peaked at $5.94M in Q3 2013.
  • 166 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.